bpc-157 psoriasis evidence Peptides for psoriasis: a complete guide to research and protocols The Peptide Reclassification Everyone's Talking

The distinction between IM and subcutaneous is unlikely to be clinically meaningful given the absence of human pharmacokinetic benchmarks for either route

Summers, Anne Thorburn, Esra Ogru, Robert Gianello, Woei-Jia Jiang, Frank M

BPC-157 is not FDA-approved, is listed by the FDA among bulk substances that may present significant safety risks, and robust human efficacy data are limited, so no reliable timeline can be stated

I.WrightP

The blanket point holds: these compounds are sold for laboratory research only, none is an approved drug, and none has an established human dose

Product Appearance and Quality Standards The solution appears as a clear, colourless liquid with no visible particles